a1L-adrenoceptor; a1A-adrenoceptor; benign prostatic hyperplasia (BPH); stress urinary incontinence (SUI); lower urinary tract; phenotype pharmacology a1-Adrenoceptors are involved in numerous physiological functions, including micturition. However, the pharmacological profile of the a1-adrenoceptor subtypes remains controversial. Here, we review the literature regarding a1-adrenoceptors in the lower urinary tract from the standpoint of a1L phenotype pharmacology. Among three a1-adrenoceptor subtypes (a1A, a1B and a1D), a1a-adrenoceptor mRNA is the most abundantly transcribed in the prostate, urethra and bladder neck of many species, including humans. In prostate homogenates or membrane preparations, a1A-adrenoceptors with high affinity for prazosin have been detected as radioligand binding sites. Functional a1-adrenoceptors in the prostate, urethra and bladder neck have low affinity for prazosin, suggesting the presence of an atypical a1-adrenoceptor phenotype (designated as a1L). The a1L-adrenoceptor occurs as a distinct binding entity from the a1A-adrenoceptor in intact segments of variety of tissues including prostate. Both the a1L-and a1A-adrenoceptors are specifically absent from Adra1A (a1a) gene-knockout mice. Transfection of a1a-adrenoceptor cDNA predominantly expresses a1A-phenotype in several cultured cell lines. However, in CHO cells, such transfection expresses a1L-and a1A-phenotypes. Under intact cell conditions, the a1L-phenotype is predominant when co-expressed with the receptor interacting protein, CRELD1a. In summary, recent pharmacological studies reveal that two distinct a1-adrenoceptor phenotypes (a1A and a1L) originate from a single Adra1A (a1a-adrenoceptor) gene, but adrenergic contractions in the lower urinary tract are predominantly mediated via the a1L-adrenoceptor. From the standpoint of phenotype pharmacology, it is likely that phenotype-based subtypes such as the a1L-adrenoceptor will become new targets for drug development and pharmacotherapy. 
Introduction
The lower urinary tract is responsible for urine storage and voiding (Andersson and Wein, 2004) . In mammalian species including humans, the bladder detrusor muscle contracts through a parasympathetic cholinergic mechanism during micturition (Abrams et al., 2006; Wess et al., 2007) . Besides the importance of the cholinergic system as the major mechanism for bladder neck muscle tone control, the adrenergic systems play significant roles in the regulation of bladder neck tone (Fig. 1) . During the storage phase, the urethra and outlet region of the bladder is contracted to maintain continence. There is good pharmacological evidence supporting the view that noradrenaline-mediated contraction of the urethral smooth muscle has an important role (Andersson and Wein, 2004) .
Among impairments in urine storage, stress urinary incontinence (SUI) is recognized as one of the most frequently occurring conditions. Deficient urethral or bladder neck closure may result in this condition. However, drug treatments for SUI are scarce, at present (Andersson and Wein, 2004) . The density of noradrenergic nerves increases markedly towards the bladder neck and urethra (Gosling et al., 1999) . a1-Adrenoceptors play important roles in both urethral and bladder neck contraction, and may be related to SUI (Andersson and Wein, 2004) .
During the voiding phase, prostatic smooth muscle tone contributes to outlet resistance regulation. Benign prostatic hyperplasia (BPH) is a common enlargement of the prostate gland that may lead to bladder outlet obstruction, and lower urinary tract symptoms. BPH is currently recognized as a target for pharmacotherapy utilizing a1-adrenoceptor antagonists. In BPH patients, enlargement of the prostate increases bladder outlet resistance and thereby impedes physiological voiding. a1-Adrenoceptor antagonists are believed to inhibit contraction of the prostate and urethra, and as a result, a1-adrenoceptor antagonists such as tamsulosin, alfuzosin and silodosin effectively reduce resistance to urinary flow and are now clinically used in BPH patients (Lefevre-Borg et al., 1993; Cooper et al., 1999; Ruffolo and Hieble, 1999; Takeda et al., 1999; Chapple, 2001; Andersson, 2002; Michel and Vrydag, 2006) .
The functional roles of a1-adrenoceptors have been highlighted through the study of their roles in lower urinary tract physiology. These are supported by numerous studies including quantification of mRNAs, anatomical localization of mRNAs, or of receptors demonstrated by ligand-binding studies (Table 1) . On the other hand, functional studies have shown discrepancies between the native a 1-adrenoceptors found in the lower urinary tract (so-called a1L-adrenoceptor) and the classical a1-adrenoceptors (a1A, a1B and a1D; receptor nomenclature follows Alexander et al., 2011) (Table 2) . Subsequent studies revealed the origin of these unique a1-adrenoceptors in the lower urinary tract (Ford et al., 1997; Gray et al., 2008; Muramatsu et al., 2008; Nishimune et al., 2010b) . In this review, we will introduce recent progress in the study of a1-adrenoceptors in the lower urinary tract as an example of the importance of phenotype pharmacology (Kenakin, 2003; Muramatsu et al., 2005; Nelson and Challiss, 2007; Su et al., 2008) . a 1 -Adrenoceptor mRNAs in the lower urinary tract Three cDNAs for distinct a1-adrenoceptor subtypes (a1a, a1b and a1d) have been cloned, and their pharmacological phenotypes are consistent with pharmacological characteristics of a1-adrenoceptors found in many native tissues (Lomasney et al., 1991; Hieble et al., 1995) (Table 2 ). In the lower urinary tract, the mRNA and protein for these three subtypes have been demonstrated (Table 1) (Michelotti et al., 2000; Michel and Vrydag, 2006; Nishimune et al., 2010a) . Among them, the a1a-adrenoceptor mRNA is the most form in the lower urinary tract of many species (Table 1) . Data from human studies indicate that the relative abundance ratio of a1a-: a1b-: a1d-adrenoceptor mRNA is approximately 70:0:30 in the prostate and 90~100:0:0~10 in the urethra (Price et al., 1993; Faure et al., 1994; Nasu et al., 1996; ; Michel and Vrydag,
Figure 1
Autonomic innervation and main functional receptors involved in controlling smooth muscle tension in lower urinary tract tissues. NA, noradrenaline; a1L, a1L-adrenoceptor; b3, b3-adrenoceptor; M3, M3-muscarinic acetylcholine receptor.
2006). Interestingly, however, the a1a-adrenoceptor mRNA detected at the tissue level disappears in cultures of human prostatic smooth muscle cells, in contrast to the consistent expression of a1b-and a1d-adrenoceptor mRNAs (Boesch et al., 1999) . The relative expression of a1a-adrenoceptor mRNA in the lower urinary tract of humans has also been examined by in situ hybridization studies. In the human prostate, a1a-adrenoceptor mRNA was mainly detected in the stroma, (Alexander et al., 2011) , the term a1A is used to refer to receptor subtype. In this review, we will use the term only for receptor phenotype in order to focus on phenotypic variation (a1A or a1L) arising from the same gene (Adra1A). To refer to receptor polypeptide, we instead use the term a1a. The superscripted numbers refer to the relevant reference and are shown here in short form; the full form is provided in the usual list of references below. 1. Scofield et al. (1995) ; 2. Walden et al. (1997) ; 3. Rokosh et al. (1994) ; 4. Homma et al. (2000) ; 5. Foster et al. (2004) ; 6. Piao et al. (2000) ; 7. Hirasawa et al. (1993) ; 8. Price et al. (1993) ; 9. Faure et al. (1994); 10. Tseng-Crank et al. (1995) ; 11. Nasu et al. (1996) ; 12. Yazawa and Honda (1993) ; 13. Hiraoka et al. (1999); 14. Su et al. (2008) ; 15. Testa et al. (1993); 16. Michel et al. (1996) ; 17. Morishima et al. (2007) ; 18. Chang et al. (2000) ; 19. Lagu et al. (2000) ; 20. Honda et al. (1985) ; 21. Delaflotte et al. (1996) ; 22. Yamagishi et al. (1996) ; 23. Hiraoka et al. (1995) ; 24. Leonardi et al. (1997) ; 25. Van der Graaf et al. (1997); 26. Forray et al. (1994); 27. Marshall et al. (1995) ; 28. Chess- Williams et al. (1996) ; 29. Eltze et al. (2001); 30. Ford et al. (1996) ; 31. Yono et al. (2004) ; 32. Nasu et al. (1998); 33. Muramatsu et al. (unpublished observation) ; 34. Honda and Nakagawa (1986) ; 35. Deplanne and Galzin (1996) ; 36. Taki et al. (1999) ; 37. Malloy et al. (1998); 38. Hampel et al. (2002) ; 39. Nomiya and Yamaguchi (2003) ; 40. Levin et al. (1988); 41. Lluel et al. (2003) ; 42. Kava et al. (1998); 43. Williams et al. (1999) . Affinity values are from Morishima et al. (2007) .
including smooth muscle cells, but not in the glandular epithelium (Walden et al., 1999) . Data regarding the expression of a1-adrenoceptor mRNA in the human bladder are inconsistent, but it appears that the expression of a1-adrenoceptor mRNA is extremely low in the bladder (Malloy et al., 1998; Nomiya and Yamaguchi, 2003) . In the human detrusor, b (mainly b3)-adrenoceptors are dominant over a-adrenoceptors, based on the fact that the normal response to noradrenaline is relaxation rather than contraction (Andersson, 1993) . Therefore, we can conclude that the functional significance of a-adrenoceptors in the detrusor contraction may be marginal or non-existent (Fig. 1) . On the other hand, the density of noradrenergic nerves increases markedly towards the bladder neck, where the smooth muscle receives a dense noradrenergic nerve supply (Gosling et al., 1999) . In the human bladder, the predominant expression of a1a-adrenoceptor mRNA in the dome, trigone and base has also been reported (Walden et al., 1997) .
Thus, the mRNA data in human urinary tract indicate that the a1a-adrenoceptor polypeptide is a potential target for pharmacotherapy in patients with BPH and SUI.
a 1 -Adrenoceptor pharmacological anomalies in the lower urinary tract
The classical a1-adrenoceptors (a1A, a1B and a1D) show high affinity for prazosin (pKi or pKB > 9) in most binding and functional studies (Lomasney et al., 1991; Hieble et al., 1995; Ford et al., 1996; Theroux et al., 1996; Taniguchi et al., 1999; Suzuki et al., 2000; Israilova et al., 2004) (Table 2 ). However, the functional a1-adrenoceptors identified in the lower urinary tract are known to be relatively resistant to prazosin (Muramatsu et al., 2009 ) (pKB =~8) (Table 1) . Thus, this pharmacological anomaly, despite the predominance of a1a-adrenoceptor mRNA, caused confusion about the a1-adrenoceptor subtypes in the lower urinary tract. Because different affinities for antagonists have traditionally been regarded as characteristic pharmacological criteria for defining novel receptors (Kenakin, 1995; Rang, 2006) , the anomalous a1-adrenoceptor showing low affinity for prazosin suggests the existence of a distinctive subtype (or phenotype).
Pharmacological heterogeneity of a1-adrenoceptors was originally reported by Drew (1985) , who first noted a wide variation in the functional affinities for yohimbine and prazosin. This evidence was confirmed in experiments with isolated blood vessels by Flavahan and Vanhoutte (1986) , and they proposed two distinct a1-adrenoceptor subtypes that could be distinguished by their different affinities for both prazosin and yohimbine (a1H and a1L according to their High or Low affinity for prazosin). This subclassification was subsequently extended by many pharmacologists and in many tissues including the lower urinary tract (Muramatsu et al., 1990; 1995; Ford et al., 1996; Testa et al., 1997; Stam et al., 1999; Argyle and McGrath, 2000) . In this subclassification, the classical a1A-, a1B-and a1D-adrenoceptors are included in the a1H group, and the anomalous a1-adrenoceptor showing low affinity for prazosin in the lower urinary tract has been reported as the a1L-adrenoceptor (Muramatsu et al., 1991; 1995; Ford et al., 1996; Langer, 1999; Nishimune et al., 2010a) . Antagonistic potencies against noradrenaline-induced contractions in rat, rabbit and human prostate are low for prazosin (pK B =~8) and a1A-antagonists (5-methylurapidil, WB4101, RS-17053), but are high for silodosin and tamsulosin (Hiraoka et al., 1995; 1999; Ford et al., 1996; Leonardi et al., 1997; Testa et al., 1997; Van der Graaf et al., 1997; Morishima et al., 2007; Su et al., 2008) . In contrast to this nomenclature, a1-adrenoceptors in the lower urinary tract have been also named as a1A-adrenoceptors in many reports (Table 1) . Therefore, there has been confusion in defining the functional a1-adrenoceptor in the lower urinary tract (Table 1) , which may in part depend on distinct subclassifications (a1H, a1L vs. a1A, a1B, a1D) .
a2-Adrenoceptor can also be detected at the mRNA and protein levels in urogenital tissues (Yablonsky et al., 1986; Michel and Vrydag, 2006) . Therefore, the anomalous characteristics of adrenergic contractions in the lower urinary tract may be associated with the a2-adrenoceptor. In fact, clonidine (a2-agonist) can produce a significant contraction in the female rabbit urethra (Larsson et al., 1986) . However, clonidine is inactive in the isolated female human urethra, while noradrenaline produces contractions through sites with low affinity for prazosin (Taki et al., 1999) . These results show that the a2-adrenoceptor is not significantly involved in the anomalous contraction in the human urethra (Ruffolo and Hieble, 1999) , although there may be relevant species differences in this adrenoceptor.
Identification of a 1 -adrenoceptors by radioligand binding assay
Because reliable subtype-specific a1a-adrenoceptor antibodies were recently reported to be unavailable (Jensen et al., 2009 ), investigation of a1-adrenoceptors at the protein level are herein summarized from radioligand-binding experiments. 3 H]-silodosin to a1-adrenoceptors in membrane preparations of the lower urinary tract has been detected, with the density of binding in the order, prostate > urethra > bladder. In the rat, rabbit and human prostate, the most abundant a1-adrenoceptor is the a1A-subtype, which has been identified as having high affinity for prazosin, tamsulosin, silodosin and other a1A-selective antagonists (5-methylurapidil and RS-17053) (Tables 1 and 2 ). Thus, low-affinity sites for prazosin (a1L-adrenoceptors) are not detected in the membrane preparations of lower urinary tract tissues and at subnanomolar concentrations of [ 3 H]-prazosin. The high abundance of the binding sites showing a1A-adrenoceptor profile in the lower urinary tract is in agreement with the mRNA expression data mentioned above.
Binding assay with membrane homogenates
Three a1-adrenoceptor cDNAs (including splice variants of a1A-adrenoceptors) were transfected in several cell lines (CHO cells, COS-7 cells, HEK293 cells, HeLa cells) and the pharmacological binding characteristics in the membrane preparations were compared with those in native tissues. The three recombinant a1-adrenoceptors showed high (subnanomolar) affinity for prazosin ( Table 2 ). The cloned a1a-adrenoceptor and its splice variants showed the same pharmacological profile as that recognized in the membrane preparations of lower urinary tract (Lomasney et al., 1991; Theroux et al., 1996; Piao et al., 2000; Suzuki et al., 2000; Ramsay et al., 2004) .
Binding assay with whole cells and intact tissues
Most radioligand-binding studies conducted to date have involved homogenates or membrane preparations of tissues or cells as a source of receptors. Because tissue/cell homogenization physically disturbs the receptor microenvironment, it may cause changes in some of the pharmacological characteristics of the receptor. Therefore, in order to retain the natural/native receptor conformation by minimizing physical agitation, whole cells or intact tissue segments must be used in binding assays.
Ford and co-workers reported that the pharmacological characteristics of the recombinant a1a-adrenoceptor can vary substantially depending upon assay conditions (Ford et al., 1997; Daniels et al., 1999) . In CHO cells expressing the recombinant a1a-adrenoceptor, prazosin and RS-17053 (a1A-selective antagonist) show substantially lower potency against functional responses (phosphatidyl inositol turnover and calcium influx) in intact cells than inhibition of radioligand binding to a1a-adrenoceptors in membrane homogenates. Furthermore, the Ki values for prazosin and RS-17053 as competitive inhibitors of [ 3 H]-prazosin binding to a1a-adrenoceptors in these CHO cells are dependent on assay conditions, with lower affinity observed when binding is conducted under more physiological conditions (culture medium, intact cells, 37°C) than under conditions commonly employed for radioligand binding assays (artificial buffer, membrane homogenates, 20°C). These observations have led to the proposal that the a1L-adrenoceptor may not represent an independent molecular entity, but rather may be an 'affinity state' of the a1A-adrenoceptor that is predominant in lower urinary tract.
Recently, a tissue segment binding method was developed and applied to numerous tissues Muramatsu et al., 2005) . In this method, tissue segments are incubated (without homogenization) in a nutrient medium such as Krebs solution during the course of ligand binding. To identify the a1-adrenoceptors having low affinity for prazosin, [
3 H]-silodosin was used instead of [ 3 H]-prazosin, because [
3 H]-prazosin at subnanomolar concentrations cannot bind sufficiently to a1L-adrenoceptors (Su et al., 2008; Muramatsu et al., 2009) . Silodosin and its tritiated radioligand are known to be of equally high affinity for both the a1A-and a1L-adrenoceptors Su et al., 2008) (Table 2) .
In segments of human, mouse and rabbit prostate, the binding of [ 3 H]-silodosin was biphasically displaced by prazosin, indicating the coexistence of high and low-affinity sites for prazosin, which correspond to a1A-and a1L-adrenoceptors (Morishima et al., 2007; Muramatsu et al., 2008; Su et al., 2008 ). This result is very different from the results obtained in homogenates, in which a single highaffinity site for prazosin (a1A-adrenoceptor) was detected. The low-affinity site for prazosin in the prostate segments also showed low affinity for some a1A-selective antagonists (RS-17053, 5-methylurapidil), but tamsulosin (which has high affinity for a 1A-, a1L-and a1D-subtypes) did not discriminate either the high-or low-affinity sites for prazosin. Similar results were obtained in studies of other tissues in which the a1L-adrenoceptor was identified as a functional receptor (Hiraizumi-Hiraoka et al., 2004; Morishima et al., 2008; Muramatsu et al., 2008; . From these observations, it was suggested that a1L-adrenoceptors (or a1L-phenotype) coexist with a1A-adrenoceptors (or a1A-phenotype) as pharmacologically distinct entities under intact segment conditions, whereas the pharmacological profile of a1L-adrenoceptors converts to the a1A-phenotype upon homogenization.
More recently, this conclusion was again confirmed in a recombinant system (Nishimune et al., 2010b) . In the CHO cell line, transfection of a1a-adrenoceptor cDNA predominantly expresses a1A-adrenoceptor phenotype, with an extremely minor proportion of a1L-adrenoceptor (less than 10% of total a1-adrenoceptor). However, persistent overexpression of the protein, cysteine-rich epidermal growth factor-like domain 1a (CRELD1a), which was found as a potential a1a-adrenoceptor-interacting protein candidate) strongly reduced the population of a1A-adrenoceptor phenotype in CHO cells (Nishimune et al., 2010b) . Although mechanisms underlying the interactions between generation of CRELD1a and a1A-adrenoceptors and a1L-adrenoceptors remain unclear, two distinct (a1L-adrenoceptor-dominant and a1A-adrenoceptor-dominant) CHO cell lines were eventually established. Under whole-cell conditions, in contrast to the a1A-adrenoceptor, pharmacological and functional properties of the established a1L-adrenoceptor show low affinity for prazosin and other a1A-adrenoceptor antagonists (5-methylurapidil, RS-17053), and the agonist and antagonist pharmacology is consistent with the profile of the a1L-adrenoceptor identified in the lower urinary tract. Therefore, from these lines of evidence, it may be now concluded that the a1L-adrenoceptor is one of the a1a-adrenoceptor gene products and occurs as an entity distinct from the a1A-adrenoceptor phenotype under conditions when the tissue/ cell is kept intact. This conclusion would also explain why a1L-adrenoceptors could not be detected after homogenization but are easily recognized in functional bioassay studies with intact tissue strips (Muramatsu et al., 2009) .
Identification of the gene encoding a 1L -adrenoceptor
Despite extensive searches at early stages after the proposal of the a1L-adrenoceptor and the subsequent completion of the human genome sequencing project, a distinct gene for the proposed a1L-adrenoceptor has not been identified. Rather, as described above, a close relationship between a1L-adrenoceptor and a1A-adrenoceptor has been considered (Ford et al., 1997; Hiraizumi-Hiraoka et al., 2004; Morishima et al., 2008) .
In order to explore this possible link between a1A-and a1L-adrenoceptors, we analysed in vivo phenotypes of mice having disrupted alleles of the classical a1-adrenoceptors (a1A, a1B and a1D) (Muramatsu et al., 2008) . The integrity of the a1L-adrenoceptors were confirmed both in terms of ligand binding properties and contractile function in the Adra1B -/-(a1b -/-) and Adra1D -/-(a1d -/-) mice as well as in the wild-type mice. In contrast, both a1L-and a1A-adrenoceptors were completely absent from the Adra1A -/-(a1a -/-) mice. These results unequivocally demonstrate that both a1A-adrenoceptors and a1L-adrenoceptors are derived from the same Adra1A (a1a) gene (Gray et al., 2008; Muramatsu et al., 2008) (Table 2) .
Observation of a 1L -adrenoceptor distribution by fluorescent probe
Alexa Fluor 488 dye conjugated with silodosin (Alexa-488-silodosin) was recently introduced as a fluorescent probe (Morishima et al., 2010) . Alexa-488-silodosin retains the high affinity and selectivity for a1A-and a1L-adrenoceptors as shown by unlabelled silodosin. Histochemical experiments with this fluorescent probe clearly showed that Alexa-488-silodosin binds to the smooth muscle but not the glandular tissue in the human prostate, and that the binding is resistant to low concentrations of prazosin. These results are in good agreement with in situ hybridization data showing selective expression of a1A-adrenoceptor mRNA in the stroma of the human prostate (Walden et al., 1999) . As the Alexa-488-silodosin can specifically label a1L-adrenoceptors, particularly by co-incubation with low concentrations of prazosin (to mask the a1A-adrenoceptor), this novel molecular probe provides a versatile tool to study a1L-adrenoceptor histochemically (Morishima et al., 2010) .
Perspective
As mentioned above, recent progress in this field clearly demonstrates that two distinct a1-adrenoceptor phenotypes (a1A and a1L) originate from a single a1a-adrenoceptor gene and coexist in some tissues. However, adrenergic contraction in the lower urinary tract is predominantly mediated through a1L-, but not a1A-adrenoceptors (Fig. 1) . In general, the affinity values (pKi or pKB) for prazosin for a1L-adrenoceptors are around 8, but recent studies reveal a further variation in prazosin affinity (pKi or pKB = 6.3-8.5) at various a1L-adrenoceptors in many tissues and species (Muramatsu et al., 2009) . This is reminiscent of the original question on a1-adrenoceptors (Drew, 1985) , suggesting further heterogeneity in a1L-adrenoceptor pharmacology. At present, the mechanisms underlying the expression of a1L-adrenoceptor phenotype and its functional predominance in several tissues remain unknown. However, it is likely that the expression of divergent a1L-adrenoceptor phenotypes is strongly dependent on any modification of the tissues of various species, rather than a simple variation of the a1a-adrenoceptor protein or additional subtypes (Muramatsu et al., 2009; Nishimune et al., 2010a) .
Recently, ample evidence has been accumulating suggesting that antagonist affinity is not necessarily constant at a given receptor expressed in different tissues/cells and examined under different assay conditions (Kenakin, 2003; Baker and Hill, 2007; Nelson and Challiss, 2007; Muramatsu et al., 2008) . The a1L-adrenoceptor exemplifies this type of variable affinity, as after homogenization, the phenotype changed from a 1L into a1A. It is likely that tissue integrity is an important factor to determine receptor properties (Su et al., 2008; Muramatsu et al., 2009) . Therefore, we may have to re-evaluate pharmacodynamic and pharmacokinetic effects of currently used drugs, and to reconstruct drug development strategies. Now, a1-antagonists, such as tamsulosin, silodosin, alfuzosin, are clinically used in BPH patients. According to the evidence mentioned above, these antagonists appear to act mainly on functional a1L-adrenoceptors in the lower urinary tract, but are not specific for the a1L-adrenoceptor. The a1L-adrenoceptors in the female urethra may be a new target in therapy for SUI. For this purpose, two a1-adrenoceptor agonists (NS-49 and Ro 115-1240) have been developed. However, these compounds are full agonists of the a1A-adrenoceptor or partial agonists of the a1A/L-adrenoceptor (Obika et al., 1995; Blue et al., 2004; Musselman et al., 2004) . Thus, more selective or specific drugs against a1L-adrenoceptors may lead to improved uroselectivity.
Conclusion
Since the successful cloning of most receptors, it has become possible to elucidate numerous physiological responses by genome-based subtype (genotypes). However, there are still some unique phenotypes showing distinct pharmacology in native tissues. The a1L-adrenoceptor is representative of this group, and originates from the a1a-adrenoceptor gene together with the a1A-adrenoceptor phenotype. In this review, we propose that different phenotypes are expressed from a single gene in native tissues ('one gene-multiple phenotypes theory'), which may explain the long controversy regarding some putative receptors, such as a1L-adrenoceptor in the lower urinary tract, and further highlights phenotypedependent pharmacology ('phenotype pharmacology').
